Columvi is a drug used for cancer patients suffering from diffuse large B-cell lymphoma DLBCL), a cancer involving a kind of white blood cell. This DLBCL comes under the subtype called Non-Hodgkin’s Lymphoma (NHL). There are about 30-40% cases of NHL cases estimated worldwide. According to the GLOBOCAN 2022 data, there are approximately 1,50,000 to 2,20,000 new cases of DLBCL found every year among 5,45,000 new cases of NHL, affecting people globally. 

Mechanism of action

Glofitamab is an active ingredient in Columvi, which is an antibody (a type of protein) manufactured in such a way to identify and bind to CD20, a type of protein that resides on the surface of healthy T cells (a type of white blood cell that takes part in the body’s natural defence and kills cancer cells). When the binding of both CD20 and CD3 occurs, the combination effects of both cancer cells and T-cells cause the cancer cells to die.

Indications

Columvi is a bispecific CD20-directed CD3 T-cell engager (unites the two types of immune cells, which are CD20 and CD3) is indicated for adults with relapse or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma after two or more after two or more lines of systemic therapy (therapy that affects the entire body).

Side effects

The most common side effects are listed below:

• cytokine release syndrome (the body releases too many inflammation-causing chemicals)
• musculoskeletal pain
• Rash
• Fatigue.

Other laboratory abnormalities include:

• A decrease in lymphocyte count, phosphate, and neutrophil count, fibrinogen, and 
• An increase in uric acid.

Major Safety concerns and monitoring

Neurological Toxicity: 

• Some people may feel sleepy or have difficulty speaking or writing.  Monitor the patient for long-term symptoms.

Infections: 

• Columvi can make the immune system weak. Monitor the patients for serious infections.

 Tumor flare:

• Monitor the patients for tumor flare after the cancer cells die.

Access Checklist:

The Glofitamab price in India varies from time to time since it is not registered in India, so we import Glofitamab from other countries through official legitimate channels at fair prices. We can help you buy Columvi in India when you get a prescription from certified doctors regarding your medical condition. We provide the medicine in the form of injection as 2.5mg/2.5mL or 10mg/10mL (1mg/1mL) in a single vial according to the dosage of the patient. Our specialised team guides you with the Glofitamab import process, as mentioned below: 

• Request for Columvi availability: We kindly request you to send a notification request for Columvi availability in India

• Form no. 12: We assist in the submission of mandatory Form No. 12. Besides this requires submission of a proper prescription approved by a Registered Medical Practitioner (RMP).

• Cross-checking of regulatory documents: We check all the prescriptions along with the patient’s medical documents to ensure eligibility for the legal Glofitamab import process.

• Import the drugs: Importation is only possible after permission from higher authorities, such as the Drugs Controller General (India).

• Navigating and delivery of the medicine: Our expert team navigates the location of Columvi availability with the suppliers who are internationally certified, checks their authenticity, and finalises it. We check the safe delivery of the medicine along with the warehouse section, shipment and finally till the door delivery of the medicine to the patient.

Conclusion

Do you want to make your journey through the import process of the rare medicines easy and transparent? 24/7QualityMeds takes utmost care of every step, be it documentation or delivery, without any confusion. We aim for your safety and satisfaction. Reach out to us today for your tailored medical needs.